The NET-CAGE analysis that inputs the "NET-RNA" currently being synthesized. New service starting in the fall of 2019! An evolved version of CAGE analysis.
In the conventional "CAGE" analysis, total RNA is input, allowing for the following: - RNA expression analysis (serving the same role as general RNA-seq) - Identification of transcription start sites (the greatest strength of CAGE, which is insufficient with RNA-seq) - Searching for transcription factor binding motifs based on the identified transcription start site data (unique to CAGE, a reverse search function of ChIP-seq) The central principle of library preparation is the "cap trap method," a unique technology developed by RIKEN that captures the cap structure at the 5' end of RNA. In this "NET-CAGE" analysis, "NET-RNA," which is currently being synthesized in the nucleus, is extracted and recovered using a unique technique and input for library preparation. (NET-RNA: Negative Elongating-Transcript: newly synthesized RNA) Generally, the lifespan of total RNA is relatively long, ranging from several hours to several days. In contrast, the eRNA (enhancer RNA) from NET-CAGE has an extremely short lifespan, being degraded within just a few minutes. "CAGE" allows us to observe the total RNA present in the cell, while "NET-CAGE" enables us to see the NET-RNA that is currently being synthesized. It has become possible to differentiate between the points we want to observe.
Inquire About This Product
basic information
- "NET-CAGE" analysis using NET-RNA as input - "CAGE" analysis using total RNA as input
Price range
P2
Delivery Time
※About 4-6 weeks.
Applications/Examples of results
Research Use Only. Please contact us for more details.
catalog（1）
Download All Catalogs
Company information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.